Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms
Journal of Alzheimer’s Disease · 2024
DOI: 10.3233/jad-230948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Stuart G Foster und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rosell Institute for Microbiome and Probiotics, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Longevity, Amyloid beta-Peptides, Bacillus subtilis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Recent advances linking gut dysbiosis with neurocognitive disorders such as Alzheimer’s disease (AD) suggest that the microbiota-gut-brain axis could be targeted for AD prevention, management, or treatment.
Objective
We sought to identify probiotics that can delay Aβ-induced paralysis.
Methods
Using C. elegans expressing human amyloid-β (Aβ) 1–42 in body wall muscles (GMC101), we assessed the effects of several probiotic strains on paralysis.
Results
We found that Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179, but not their supernatants or heat-treated forms, delayed paralysis and prolonged lifespan without affecting the levels of amyloid-β aggregates. To uncover the mechanism involved, we explored the role of two known pathways involved in neurogenerative diseases, namely mitophagy, via deletion of the mitophagy factor PINK-1, and fatty acid desaturation, via deletion of the Δ9 desaturase FAT-5. Pink-1 deletion in GMC101 worms did not modify the life-prolonging and anti-paralysis effects of HA-114 but reduced the protective effect of R0179 against paralysis without affecting its life-prolonging effect. Upon fat5 deletion in GMC101 worms, the monounsaturated C14:1 and C16:1 FAs conserved their beneficial effect while the saturated C14:0 and C16:0 FAs did not. The beneficial effects of R0179 on both lifespan and paralysis remained unaffected by fat-5 deletion, while the beneficial effect of HA-114 on paralysis and lifespan was significantly reduced.
Conclusions
Collectively with clinical and preclinical evidence in other models, our results suggest that HA-114 or R0179 could be studied as potential therapeutical adjuncts in neurodegenerative diseases such as AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rosell Institute for Microbiome and Probiotics, Montreal, QC, Canada.
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal and Department of Neuroscience, University of Montreal, Montreal, QC, Canada.
- Lallemand Health Solutions Inc., Blagnac Cedex, France.
Zitieren
APA
Foster, S. G., Mathew, S., Labarre, A., Parker, J. A., Tompkins, T. A., & Binda, S. (2024). Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-230948
Vancouver
Foster SG, Mathew S, Labarre A, Parker JA, Tompkins TA, Binda S. Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-230948
BibTeX
@article{Foster2024,
author = {Foster, Stuart G and Mathew, Shibi and Labarre, Audrey and Parker, J Alex and Tompkins, Thomas A and Binda, Sylvie},
title = {Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.3233/jad-230948}
}
EUVIMED